Contact this trialFirst, we need to learn more about you.
Nucleoside Metabolic Inhibitor
Nintedanib + Azacitidine for Acute Myeloid Leukemia
Recruiting3 awardsPhase 1
Chicago, Illinois
This trial is testing a new drug, nintedanib, to see if it is effective in treating AML in older adults who cannot have standard intensive chemotherapy. The side effects of the combination will also be studied.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service